secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001104659-25-050226
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax receives FDA approval for Nuvaxovid COVID-19 vaccine; triggers $175M Sanofi milestone
--------------------------------------------------------------------------------

- FDA approves BLA for Nuvaxovid for COVID-19 in adults 65+ and high-risk individuals 12-64.
- Approval triggers $175M milestone payment from Sanofi under May 2024 Collaboration and License Agreement.
- FDA requests new Phase 4 postmarketing efficacy trial in 50-64 age group without high-risk conditions; Novavax working with Sanofi on funding.
- Novavax reiterates FY2025 R&D+SG&A guidance of $475-525M; projects ~$350M for FY2026 and ~$250M for FY2027.
- Expects commercial delivery of 2025-2026 COVID-19 vaccine formula in US this Fall with Sanofi, pending VRBPAC recommendation May 22.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925050226/0001104659-25-050226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925050226/tm2515521d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-050226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer